{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"}],"units":"Participants"}],"description":"Response on 2 consecutive months during active treatment with anakinra alone or in combination with dexamethasone.\n\nResponse criteria is the same as in Primary Outcome Measure.","groups":[{"description":"Patients in this outcome received both Anakinra (100mg daily subcutaneously administered) and dexamethasone (either 20mg/week OR 40mg days 1-4, 9-12, 17-20 every 28 days during odd cycles OR 40 mg days 1-4 every 28 days during even cycles)","id":"OG000","title":"Anakinra With Dexamethasone"}],"paramType":"NUMBER","populationDescription":"Only participants who received Anakinra with dexamethasone were analyzed.","reportingStatus":"POSTED","timeFrame":"During Active treatment (up to 5 years)","title":"Number of Patients With Response to Treatment With Dexamethasone and Anakinra","type":"SECONDARY","unitOfMeasure":"participants"}